Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | POLA1 | P09884 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669690 | 0.88 | KCNH2 (0.50) | KCNH2POLA1RXFP1ALDH1A1F10 | |
| SCHEMBL6668933 | 0.84 | KCNH2 (0.52) | KCNH2POLA1EGLN1ALDH1A1MLLT1 | |
| SCHEMBL6666276 | 0.83 | EGLN1 (0.47) | POLA1RXFP1EGLN1 | |
| SCHEMBL6665763 | 0.82 | KCNH2 (0.54) | KCNH2POLA1RXFP1ALDH1A1F10 | |
| SCHEMBL6723020 | 0.81 | KCNH2 (0.47) | KCNH2POLA1RXFP1ALDH1A1 | |
| SCHEMBL6716807 | 0.80 | KCNH2 (0.46) | KCNH2POLA1RXFP1ALDH1A1MLLT1 | |
| SCHEMBL6201283 | 0.80 | KCNH2 (0.54) | KCNH2POLA1RXFP1ALDH1A1F10 | |
| SCHEMBL6280316 | 0.80 | KCNH2 (0.67) | KCNH2POLA1 | |
| SCHEMBL6707995 | 0.79 | KCNH2 (0.61) | KCNH2POLA1RXFP1ALDH1A1F10 | |
| SCHEMBL6716949 | 0.79 | RXFP1 (0.49) | KCNH2POLA1RXFP1EGLN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | claimed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| US-6562822-B2 | Heterocyle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | claimed |
| EP-1299360-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| US-20020188004-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-12-12 | — | — | US | claimed |
| WO-2002004422-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | disclosed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| US-6562822-B2 | Heterocyle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
| EP-1299360-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020188004-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-12-12 | — | — | US | disclosed |
| WO-2002004422-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | KCNH2 4095/4885POLA1 2447/4885RXFP1 47/4885 |
| US-20020188004-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | KCNH2 919/4885POLA1 267/4885RXFP1 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.